Abstract
Background: Adolescent patients with major depressive disorders (MDD) frequently co-occur with headache, contributing to substantial disease burden and social functional impairment. Repetitive transcranial magnetic stimulation (rTMS) has been supported for MDD and pain conditions, but clinical evidence for a combined affect and pain network targeting strategy in comorbid phenotypes remains limited. Case presentation: A 16-year-old male student presented with a 2-year history of depression accompanied by paroxysmal headache. We administered a dual-target rTMS protocol targeting the dorsolateral prefrontal cortex and primary motor cortex. After 2 weeks of treatment (40 sessions), the patient’s depressive and headache symptoms improved significantly. Conclusions: This case suggests that an intensified dual-target rTMS approach engaging both affect regulation and pain modulation targets may be feasible for adolescents with comorbid depression and headache. Prospective studies are needed to determine optimal parameters, durability, and safety.
Introduction
Major Depressive Disorder (MDD) and chronic headaches are highly comorbid, particularly among adolescent populations. This intersection of psychiatric and neurological symptoms often leads to severe functional impairment and a higher resistance to standard pharmacological interventions.
While repetitive transcranial magnetic stimulation (rTMS) is an established, non-invasive neuromodulation technique for treating depression (typically targeting the dorsolateral prefrontal cortex, DLPFC) and chronic pain (typically targeting the primary motor cortex, M1), clinical evidence for a combined, dual-target strategy for comorbid cases is scarce. This case report explores the efficacy of an accelerated, dual-target rTMS protocol in a 16-year-old patient who had not responded adequately to conventional drug therapies.
Case Presentation
The patient, a 16-year-old male, presented with a two-year history of low mood, anhedonia, and paroxysmal headaches. These symptoms were accompanied by declines in sleep quality and appetite, leading to significant functional impairment. Initial evaluations, including MRI and EEG, showed no obvious structural or electrical abnormalities. He was initially diagnosed with MDD and prescribed sertraline (50–100 mg/day). After two months without marked improvement, he was switched to duloxetine (40–120 mg/day). While the switch resulted in partial improvement of depressive symptoms (HAMD-24 score of 35), his headaches remained severe (VAS score of 7).
Therapeutic Intervention
Given the treatment-resistant nature of the comorbidity, the clinical team designed an intensified, dual-target rTMS protocol. The treatment was administered over 10 working days, totaling 40 sessions (4 sessions per day with 2-hour intervals).
The protocol targeted two distinct neural networks:
- Affect Regulation: Low-frequency (1 Hz) stimulation was applied to the right DLPFC at 90% resting motor threshold (RMT) for 900 pulses. The right-side, low-frequency approach was selected to minimize seizure risk and improve tolerability in a pediatric patient.
- Pain Modulation: High-frequency (10 Hz) stimulation was applied to the left M1 at 80% RMT for 600 pulses.
Results and Outcomes
The dual-target approach yielded rapid and significant clinical improvements. By the end of the two-week treatment block, the patient's HAMD-24 score dropped from 35 (severe depression) to 3 (remission). Similarly, his pain intensity on the Visual Analog Scale (VAS) decreased from 7 to 1.
Beyond clinical scales, physiological monitoring via near-infrared spectroscopy (NIRS) during a verbal fluency task showed a marked increase in oxygenated hemoglobin in the prefrontal cortex post-treatment. This objective measure corroborated the patient's reported functional recovery. Importantly, the patient tolerated the high-intensity protocol well, with no adverse reactions reported across the 40 sessions.
Discussion
The rapid remission observed in this case suggests a potential synergy between the affect regulation and pain modulation networks. The brain's pain and mood circuits are deeply intertwined; stimulating the right DLPFC may modulate pain perception, while relieving chronic pain through M1 stimulation can indirectly alleviate depressive symptoms.
The success of this accelerated protocol (4 sessions per day) aligns with emerging trends in psychiatric neuromodulation, such as Stanford Neuromodulation Therapy (SNT), which seeks to compress treatment timelines to achieve faster clinical results. This case demonstrates that such intensified protocols are feasible and safe for adolescent patients.
Conclusion
This case report highlights the potential of dual-target rTMS as a rapid-acting intervention for adolescents with comorbid depression and headache. While the results are promising, the inherent limitations of a single-case study mean these findings cannot yet be generalized. Prospective, randomized controlled trials with larger cohorts are necessary to validate this approach, optimize stimulation parameters, and assess the long-term durability of the treatment effect.
Summary updated